After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
On June 13, 2019, the new CTS Laboratory Information System was successfully implemented in Cha...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
CTS Spotlight at 2018 AABB Annual Meeting Sunday, October 14, 2018 at 1:30 PM: Scientific Oral ...
As the US coast prepares for Hurricane Florence to make landfall, we have received importan...
Celebrate National Blood Donor Month throughout January by inviting eligible individuals to donate b...
On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor anti...